Article By:
Dr. Hung Tran
Tuesday, September 9, 2014 9:45 PM EDT
MannKind Corporation and Sanofi are poised to launch a new form of fast acting insulin called Afrezza. But will investors be able to forget their disappointment Nektar Therapeutics' insulin inhaler, Exubera, to recognize Afrezza's value?